BioFinlandin jäsen

Seqvera works on data solutions and evaluation for companies developing biomaterials, medical devices (MDR 2017/745), ATMP (1394/2007), hybrid and combined products and assist them in their R&D and clinical translations.

Seqvera has several patents on the technology including invariant testing of biomaterials (BEST method) and injectability testing. Through several projects, including EU GreenDeal, Seqvera is engaged in pharmaceuticals safety testing as well as advanced therapy products such as immortalized perinatal derivatives and solutions for cardiovascular diseases.